1-20 of 42
Geoffrey R. Oxnard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation

Christian D. Rolfo, Russell W. Madison, Lincoln W. Pasquina, Derek W. Brown, Yanmei Huang, Jason D. Hughes, Ryon P. Graf, Geoffrey R. Oxnard, Hatim Husain
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2452–2460.
https://doi.org/10.1158/1078-0432.CCR-23-3321
Published: 03 June 2024
View article titled, Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Open the PDF for Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types

Pashtoon M. Kasi, Jessica K. Lee, Lincoln W. Pasquina, Brennan Decker, Pierre Vanden Borre, Dean C. Pavlick, Justin M. Allen, Christine Parachoniak, Julia C. F. Quintanilha, Ryon P. Graf, Alexa B. Schrock, Geoffrey R. Oxnard, Christine M. Lovly, Hanna Tukachinsky, Vivek Subbiah
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (4): 836–848.
https://doi.org/10.1158/1078-0432.CCR-23-2693
Published: 16 February 2024
View article titled, Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Open the PDF for Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer

Bruna Pellini, Russell W. Madison, Merrida A. Childress, Shoshana T. Miller, Ole Gjoerup, Jason Cheng, Richard S.P. Huang, Michael Krainock, Pratyush Gupta, Wei Zou, David S. Shames, Solomon Moshkevich, Marcus Ballinger, Minetta C. Liu, Amanda Young, Minu K. Srivastava, Geoffrey R. Oxnard, Mark A. Socinski
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4596–4605.
https://doi.org/10.1158/1078-0432.CCR-23-1578
Published: 14 November 2023
View article titled, Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
Open the PDF for Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer

Alex Chehrazi-Raffle, Hanna Tukachinsky, Eamon Toye, Smruthy Sivakumar, Alexa B. Schrock, Hannah E. Bergom, Hedyeh Ebrahimi, Sumanta Pal, Tanya Dorff, Neeraj Agarwal, Brandon A. Mahal, Geoffrey R. Oxnard, Justin Hwang, Emmanuel S. Antonarakis
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 3948–3957.
https://doi.org/10.1158/1078-0432.CCR-23-1393
Published: 02 October 2023
View article titled, Unique Spectrum of Activating <em>BRAF</em> Alterations in Prostate Cancer
Open the PDF for Unique Spectrum of Activating <em>BRAF</em> Alterations in Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Jhanelle E. Gray, Myung-Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3340–3351.
https://doi.org/10.1158/1078-0432.CCR-22-3146
Published: 01 September 2023
View article titled, Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Open the PDF for Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA in another window
Includes: Supplementary data
Journal Articles

Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers

Julia Rotow, Jyoti D. Patel, Matthew P. Hanley, Helena Yu, Mark Awad, Jonathan W. Goldman, Hovav Nechushtan, Matthias Scheffler, Chih-Hsi S. Kuo, Senthil Rajappa, Guilherme Harada, Sarah Clifford, Alison Santucci, Laura Silva, Rebecca Tupper, Geoffrey R. Oxnard, Jennifer Kherani, Alexander Drilon
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 2979–2987.
https://doi.org/10.1158/1078-0432.CCR-22-2189
Published: 15 August 2023
View article titled, Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <em>EGFR</em>-Mutant and <em>RET</em> Fusion-Positive Lung Cancers
Open the PDF for Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of <em>EGFR</em>-Mutant and <em>RET</em> Fusion-Positive Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma

Hope S. Rugo, Kira Raskina, Alexa B. Schrock, Russell W. Madison, Ryon P. Graf, Ethan S. Sokol, Smruthy Sivakumar, Jessica K. Lee, Virginia Fisher, Geoffrey R. Oxnard, Hanna Tukachinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1056–1067.
https://doi.org/10.1158/1078-0432.CCR-22-2115
Published: 14 March 2023
View article titled, Biology and Targetability of the Extended Spectrum of <em>PIK3CA</em> Mutations Detected in Breast Carcinoma
Open the PDF for Biology and Targetability of the Extended Spectrum of <em>PIK3CA</em> Mutations Detected in Breast Carcinoma in another window
Includes: Supplementary data
Journal Articles

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Kim N. Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 81–91.
https://doi.org/10.1158/1078-0432.CCR-22-0931
Published: 04 January 2023
View article titled, Detection of <em>BRCA1</em>, <em>BRCA2</em>, and <em>ATM</em> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Open the PDF for Detection of <em>BRCA1</em>, <em>BRCA2</em>, and <em>ATM</em> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound in another window
Includes: Supplementary data
Journal Articles

SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer

Umang Swami, Ryon P. Graf, Roberto H. Nussenzveig, Virginia Fisher, Hanna Tukachinsky, Alexa B. Schrock, Gerald Li, Jeffrey S. Ross, Nicolas Sayegh, Nishita Tripathi, Vinay Mathew Thomas, Geoffrey R. Oxnard, Emmanuel S. Antonarakis, Neeraj Agarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (22): 4917–4925.
https://doi.org/10.1158/1078-0432.CCR-22-2228
Published: 14 November 2022
View article titled, SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in <em>De Novo</em> Metastatic Castration-Sensitive Prostate Cancer
Open the PDF for SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in <em>De Novo</em> Metastatic Castration-Sensitive Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA

Jessica K. Lee, Mehlika Hazar-Rethinam, Brennan Decker, Ole Gjoerup, Russell W. Madison, Daniel S. Lieber, Jon H. Chung, Alexa B. Schrock, James Creeden, Jeffrey Venstrom, Brian Alexander, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 728–737.
https://doi.org/10.1158/1078-0432.CCR-21-2136
Published: 15 February 2022
View article titled, The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Open the PDF for The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA in another window
Includes: Supplementary data
Journal Articles

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho, Herbert H. Loong, Caroline E. McCoach, Jared Weiss, Yu Jung Kim, Lyudmila Bazhenova, Keunchil Park, Haruko Daga, Benjamin Besse, Oliver Gautschi, Christian Rolfo, Edward Y. Zhu, Jennifer F. Kherani, Xin Huang, Suhyun Kang, Alexander Drilon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4160–4167.
https://doi.org/10.1158/1078-0432.CCR-21-0800
Published: 01 August 2021
View article titled, Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Open the PDF for Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial in another window
Includes: Supplementary data
Journal Articles

Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA

Xiaoji Chen, Zhao Dong, Earl Hubbell, Kathryn N. Kurtzman, Geoffrey R. Oxnard, Oliver Venn, Collin Melton, Christina A. Clarke, Rita Shaknovich, Ting Ma, Gerry Meixiong, Michael V. Seiden, Eric A. Klein, Eric T. Fung, Minetta C. Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4221–4229.
https://doi.org/10.1158/1078-0432.CCR-21-0417
Published: 01 August 2021
View article titled, Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA
Open the PDF for Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA in another window
Includes: Supplementary data
Journal Articles

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms

Hanna Tukachinsky, Russell W. Madison, Jon H. Chung, Ole V. Gjoerup, Eric A. Severson, Lucas Dennis, Bernard J. Fendler, Samantha Morley, Lei Zhong, Ryon P. Graf, Jeffrey S. Ross, Brian M. Alexander, Wassim Abida, Simon Chowdhury, Charles J. Ryan, Karim Fizazi, Tony Golsorkhi, Simon P. Watkins, Andrew Simmons, Andrea Loehr, Jeffrey M. Venstrom, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (11): 3094–3105.
https://doi.org/10.1158/1078-0432.CCR-20-4805
Published: 01 June 2021
View article titled, Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Open the PDF for Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms in another window
Includes: Supplementary data
Journal Articles

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Erin M. Bertino, Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura, Zofia Piotrowska, D. Ross Camidge, Thomas E. Stinchcombe, Christine Hann, Jyoti Malhotra, Liza C. Villaruz, Cloud P. Paweletz, Christie L. Lau, Lynette Sholl, Naoko Takebe, Jeffrey A. Moscow, Geoffrey I. Shapiro, Pasi A. Jänne, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1604–1611.
https://doi.org/10.1158/1078-0432.CCR-20-4084
Published: 15 March 2021
View article titled, Phase IB Study of Osimertinib in Combination with Navitoclax in <em>EGFR</em>-mutant NSCLC Following Resistance to Initial <em>EGFR</em> Therapy (ETCTN 9903)
Open the PDF for Phase IB Study of Osimertinib in Combination with Navitoclax in <em>EGFR</em>-mutant NSCLC Following Resistance to Initial <em>EGFR</em> Therapy (ETCTN 9903) in another window
Includes: Supplementary data
Journal Articles

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib

Ezra Y. Rosen, Melissa L. Johnson, Sarah E. Clifford, Romel Somwar, Jennifer F. Kherani, Jieun Son, Arrien A. Bertram, Monika A. Davare, Eric Gladstone, Elena V. Ivanova, Dahlia N. Henry, Elaine M. Kelley, Mika Lin, Marina S.D. Milan, Binoj C. Nair, Elizabeth A. Olek, Jenna E. Scanlon, Morana Vojnic, Kevin Ebata, Jaclyn F. Hechtman, Bob T. Li, Lynette M. Sholl, Barry S. Taylor, Marc Ladanyi, Pasi A. Jänne, S. Michael Rothenberg, Alexander Drilon, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (1): 34–42.
https://doi.org/10.1158/1078-0432.CCR-20-2278
Published: 04 January 2021
View article titled, Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Open the PDF for Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib in another window
Includes: Supplementary data
Journal Articles

Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation

Michael L. Maitland, Julia Wilkerson, Sanja Karovic, Binsheng Zhao, Jessica Flynn, Mengxi Zhou, Patrick Hilden, Firas S. Ahmed, Laurent Dercle, Chaya S. Moskowitz, Ying Tang, Dana E. Connors, Stacey J. Adam, Gary Kelloff, Mithat Gonen, Tito Fojo, Lawrence H. Schwartz, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (24): 6464–6474.
https://doi.org/10.1158/1078-0432.CCR-20-1493
Published: 15 December 2020
View article titled, Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation
Open the PDF for Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation in another window
Includes: Supplementary data
Journal Articles

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

Alissa J. Cooper, Yoshihisa Kobayashi, Dewey Kim, Sarah E. Clifford, Sasha Kravets, Suzanne E. Dahlberg, Emily S. Chambers, Jiaqi Li, Deepa Rangachari, Tom Nguyen, Daniel B. Costa, Michael S. Rabin, Nikhil Wagle, Lynette M. Sholl, Pasi A Jänne, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 4072–4079.
https://doi.org/10.1158/1078-0432.CCR-20-0397
Published: 03 August 2020
View article titled, Identification of a RAS-activating <em>TMEM87A–RASGRF1</em> Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Open the PDF for Identification of a RAS-activating <em>TMEM87A–RASGRF1</em> Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract IA12: Response in plasma cfDNA as an early marker of treatment effect in advanced cancer

Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): IA12.
https://doi.org/10.1158/1557-3265.LiqBiop20-IA12
Published: 01 June 2020
View article titled, Abstract IA12: Response in plasma cfDNA as an early marker of treatment effect in advanced cancer
Journal Articles

Abstract A28: SPACEWALK: Plasma NGS for remote evaluation of ALK drug resistance in advanced NSCLC

Marissa N. Lawrence, Rubii M. Tamen, Alicia Sable-Hunt, Seyed Ali Hosseini, George R. Simon, Jonathan W. Riess, Geoffrey R. Oxnard
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A28.
https://doi.org/10.1158/1557-3265.LiqBiop20-A28
Published: 01 June 2020
View article titled, Abstract A28: SPACEWALK: Plasma NGS for remote evaluation of ALK drug resistance in advanced NSCLC
Journal Articles

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC

Gonzalo Recondo, Magda Bahcall, Liam F. Spurr, Jianwei Che, Biagio Ricciuti, Giulia C. Leonardi, Ying-Chun Lo, Yvonne Y. Li, Giuseppe Lamberti, Tom Nguyen, Marina S.D. Milan, Deepti Venkatraman, Renato Umeton, Cloud P. Paweletz, Adem Albayrak, Andrew D. Cherniack, Kristin S. Price, Stephen R. Fairclough, Mizuki Nishino, Lynette M. Sholl, Geoffrey R. Oxnard, Pasi A. Jänne, Mark M. Awad
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2615–2625.
https://doi.org/10.1158/1078-0432.CCR-19-3608
Published: 01 June 2020
View article titled, Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
Open the PDF for Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC in another window
Includes: Supplementary data